Fibrates as therapy for osteoarthritis and rheumatoid arthritis? A systematic review

Therapeutic Advances in Musculoskeletal Disease

Volumn 5, Issue 1, 2013, Pages 33-44

  Van Eekeren, Inge C M ^a   Bastiaansen Jenniskens, Yvonne M ^a   Verhaar, Jan A N ^a   Clockaerts, Stefan ^a   Lubberts, Eric ^a   Van Osch, Gerjo J V M ^a   Bierma Zeinstra, Sita M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

fibrates; osteoarthritis; peroxisome proliferator activated receptor ; rheumatoid arthritis

Indexed keywords

BEZAFIBRATE; C REACTIVE PROTEIN; CLOBUZARIT; FIBRIC ACID DERIVATIVE;

ADJUVANT ARTHRITIS; BLOOD LEVEL; CELL INFILTRATION; DATA ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG RESPONSE; DYSLIPIDEMIA; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; IMMUNOCOMPETENT CELL; IN VITRO STUDY; IN VIVO STUDY; JOINT SWELLING; NONHUMAN; OSTEOARTHRITIS; OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYSTEMATIC REVIEW;

EID: 84878345663     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X12468659     Document Type: Review

References (59)

1. Alagona P. Jr (2010) Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia. Vasc Health Risk Manag 6: 351–362.
2. Aspden R. (2008) Osteoarthritis: a problem of growth not decay? Rheumatology (Oxford) 47: 1452–1460.
3. Baker J. Walsh P. Mulhall K. (2011) Statins: a potential role in the management of osteoarthritis? Joint Bone Spine 78: 31–34.
4. Bird H. Dixon J. Finney P. Leatham P. Lowe J. Pickup M. et al. (1983) A Clinical and biochemical evaluation of clozic, a novel disease modifying drug in rheumatoid arthritis. Clin Exp Rheumatol 1: 93–99.
5. Bloxham D. Bradshaw D. Cashin C. Dodge B. Lewis E. Westmacott D. et al. (1990) Biologic properties of romazarit (Ro 31-3948), a potential disease-modifying antirheumatic drug. J Pharmacol Exp Ther 252: 1331–1340.
6. Bondeson J. Blom A. Wainwright S. Hughes C. Caterson B. van Den Berg W. (2010) The role of synovial macrophages and macrophage-produced mediators in driving inflammatory and destructive responses in osteoarthritis. Arthritis Rheum 62: 647–657.
7. Bordji K. Grillasca J. Gouze J. Magdalou J. Schohn H. Keller J. et al. (2000) Evidence for the presence of peroxisome proliferator-activated receptor (PPAR) alpha and gamma and retinoid Z receptor in cartilage. PPARgamma activation modulates the effects of interleukin-1beta on rat chondrocytes. J Biol Chem 275: 12243–12250.
8. Castillero E. Nieto-Bona M. Fernandez-Galaz C. Martin A. Lopez-Menduina M. Granado M. et al. (2011) Fenofibrate, a PPAR{alpha} agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy. Am J Physiol Endocrinol Metab 300: E790–E799.
9. Chan B. Gartland A. Wilson P. Buckley K. Dillon J. Fraser W. et al. (2007) PPAR agonists modulate human osteoclast formation and activity in vitro. Bone 40: 149–159.
10. Cheng S. Afif H. Martel-Pelletier J. Pelletier J. Li X. Farrajota K. et al. (2004) Activation of peroxisome proliferator-activated receptor gamma inhibits interleukin-1beta-induced membrane-associated prostaglandin E 2 synthase-1 expression in human synovial fibroblasts by interfering with EGR-1. J Biol Chem 279: 22057–22065.
11. Chung J. Seo A. Chung S. Kim M. Leeuwenburgh C. Yu B. et al. (2008) Molecular mechanism of PPAR in the regulation of age-related inflammation. Ageing Res Rev 7: 126–136.
12. Clockaerts S. Bastiaansen-Jenniskens Y. Feijt C. Verhaar J. Somville J. de Clerck L. et al. (2011) Peroxisome proliferator activated receptor alpha activation decreases inflammatory and destructive responses in osteoarthritic cartilage. Osteoarthritis Cartilage 19: 895–902.
13. Clockaerts S. Bastiaansen-Jenniskens Y. Runhaar J. van Osch G. van Offel J. Verhaar J. et al. (2010) The infrapatellar fat pad should be considered as an active osteoarthritic joint tissue: a narrative review. Osteoarthritis Cartilage 18: 876–882.
14. Clockaerts S. Osch G. Bastiaansen-Jenniskens Y. Verhaar J. Glabbeek F. Meurs J. et al. (2012) Statin use is associated with reduced incidence and progression of knee osteoarthritis in the Rotterdam Study. Ann Rheum Dis 71: 642–647.
15. Conaghan P. Vanharanta H. Dieppe P. (2005) Is progressive osteoarthritis an atheromatous vascular disease? Ann Rheum Dis 64: 1539–1541.
16. Crisafulli C. Cuzzocrea S. (2009) The role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor alpha (PPAR-alpha) in the regulation of inflammation in macrophages. Shock 32: 62–73.
17. Davies-Tuck M. Hanna F. Davis S. Bell R. Davison S. Wluka A. et al. (2009) Total cholesterol and triglycerides are associated with the development of new bone marrow lesions in asymptomatic middle-aged women – a prospective cohort study. Arthritis Res Ther 11: R181.
18. Dixon J. Sitton N. Surrall K. Martin M. Pickup M. Bird H. (1983) The effect of drugs on serum histidine levels in rheumatoid arthritis. Rheumatol Int 3: 145–149.
19. Fahmi H. Di Battista J. Pelletier J. Mineau F. Ranger P. Martel-Pelletier J. (2001) Peroxisome proliferator-activated receptor gamma activators inhibit interleukin-1beta-induced nitric oxide and matrix metalloproteinase 13 production in human chondrocytes. Arthritis Rheum 44: 595–607.
20. Farnier M. Marcereuil D. de Niet S. Ducobu J. Steinmetz A. Retterstol K. et al. (2012) Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials. Clin Drug Investig 32: 281–291.
21. Findlay D. (2007) Vascular pathology and osteoarthritis. Rheumatology (Oxford) 46: 1763–1768.
22. Forster P. McConkey B. (1986) The effect of antirheumatic drugs on circulating immune complexes in rheumatoid arthritis. Q J Med 58: 29–42.
23. Francois M. Richette P. Tsagris L. Fitting C. Lemay C. Benallaoua M. et al. (2006) Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes. Arthritis Rheum 54: 1233–1245.
24. Goto M. (2010) A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis. Mod Rheumatol 20: 238–243.
25. Henrotin Y. Bruckner P. Pujol J. (2003) The role of reactive oxygen species in homeostasis and degradation of cartilage. Osteoarthritis Cartilage 11: 747–755.
26. Hoeven T. Kavousi M. Clockaerts S. Kerkhof H. van Meurs J. Franco O. et al. (2012) Association of atherosclerosis with presence and progression of osteoarthritis: the Rotterdam Study. Ann Rheum Dis 6 May (Epub ahead of print).
27. Hulejova H. Baresova V. Klezl Z. Polanska M. Adam M. Senolt L. (2007) Increased level of cytokines and matrix metalloproteinases in osteoarthritic subchondral bone. Cytokine 38: 151–156.
28. Hunter D. (2009) Osteoarthritis. Med Clin North Am 93: xv–xviii.
29. Jackson S. Demer L. (2000) Peroxisome proliferator-activated receptor activators modulate the osteoblastic maturation of MC3T3-E1 preosteoblasts. FEBS Lett 471: 119–124.
30. Jenkins J. Hardy K. McMurray R. (2002) The pathogenesis of rheumatoid arthritis: a guide to therapy. Am J Med Sci 323: 171–180.
31. Ji Y. Wang Z. Li Z. Liu J. (2010) Modulation of LPS-mediated inflammation by fenofibrate via the TRIF-dependent TLR 4 signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem 25: 631–640.
32. Kakinuma T. Yasuda T. Nakagawa T. Hiramitsu T. Akiyoshi M. Akagi M. et al. (2004) Lectin-like oxidized low-density lipoprotein receptor 1 mediates matrix metalloproteinase 3 synthesis enhanced by oxidized low-density lipoprotein in rheumatoid arthritis cartilage. Arthritis Rheum 50: 3495–3503.
33. Katz J. Agrawal S. Velasquez M. (2010) Getting to the heart of the matter: osteoarthritis takes its place as part of the metabolic syndrome. Curr Opin Rheumatol 22: 512–519.
34. Krysiak R. Gdula-Dymek A. Okopien B. (2011) Monocyte-Suppressing Effect of Bezafibrate but Not Omega-3 Fatty Acids in Patients with Isolated Hypertriglyceridaemia. Basic Clin Pharmacol Toxicol 109: 23–29.
35. Lalloyer F. Staels B. (2010) Fibrates, glitazones, and peroxisome proliferator-activated receptors. Arterioscler Thromb Vasc Biol 30: 894–899.
36. Lazzerini P. Capecchi P. Selvi E. Lorenzini S. Bisogno S. Baldari C. et al. (2010) Statins and the joint: multiple targets for a global protection? Semin Arthritis Rheum 40: 430–446.
37. McConkey B. Amos R. Billingham M. Constable T. Crockson R. Crockson A. et al. (1980) Rheumatoid arthritis: effects of a new agent (ICI 55 897) on serum acute phase proteins and the erythrocyte sedimentation rate. Ann Rheum Dis 39: 18–21.
38. Miller D. Spence J. (1998) Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 34: 155–162.
39. Nurmohamed M. (2007) Atherogenic lipid profiles and its management in patients with rheumatoid arthritis. Vasc Health Risk Manag 3: 845–852.
40. Nurmohamed M. Dijkmans B. (2009) Dyslipidaemia, statins and rheumatoid arthritis. Ann Rheum Dis 68: 453–455.
41. Okamoto H. Iwamoto T. Kotake S. Momohara S. Yamanaka H. Kamatani N. (2005) Inhibition of NF-kappab signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis. Clin Exp Rheumatol 23: 323–330.
42. Paraskevas K. (2008) Statin treatment for rheumatoid arthritis: a promising novel indication. Clin Rheumatol 27: 281–287.
43. Poleni P. Bianchi A. Etienne S. Koufany M. Sebillaud S. Netter P. et al. (2007) Agonists of peroxisome proliferators-activated receptors (PPAR) alpha, beta/delta or gamma reduce transforming growth factor (TGF)-beta-induced proteoglycans’ production in chondrocytes. Osteoarthritis Cartilage 15: 493–505.
44. Poleni P. Etienne S. Velot E. Netter P. Bianchi A. (2010) Activation of PPARs α, β/δ, and γ impairs TGF-β1-induced collagens’ production and modulates the TIMP-1/MMPS balance in three-dimensional cultured chondrocytes. PPAR Res 2010: 635912.
45. Pratt A. Isaacs J. Mattey D. (2009) Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract Res Clin Rheumatol 23: 37–48.
46. Reynolds P. McLeod M. Dick W. (1981) Clozic (ICI 55,897) in rheumatoid arthritis – a controlled comparison with gold. Br J Clin Pract 35: 306–308.
47. Ridker P. Danielson E. Fonseca F. Genest J. Gotto A. Jr Kastelein J. et al. (2009) Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the Jupiter trial. Lancet 373: 1175–1182.
48. Ritchie D. Boyle J. McInnes J. Jasani M. Dalakos T. Grieveson P. et al. (1969) Evaluation of a simple articular index for joint tenderness in rheumatoid arthritis. Ann Rheum Dis 28: 196.
49. Rubenfire M. Brook R. Rosenson R. (2010) Treating mixed hyperlipidemia and the atherogenic lipid phenotype for prevention of cardiovascular events. Am J Med 123: 892–898.
50. Schett G. Firestein G. (2010) Mr Outside and Mr Inside: classic and alternative views on the pathogenesis of rheumatoid arthritis. Ann Rheum Dis 69: 787–789.
51. Shahin D. Eltoraby E. Mesbah A. Houssen M. (2010) Insulin resistance in early untreated rheumatoid arthritis patients. Clin Biochem 43: 661–665.
52. Simopoulou T. Malizos K. Poultsides L. Tsezou A. (2010) Protective effect of atorvastatin in cultured osteoarthritic chondrocytes. J Orthop Res 28: 110–115.
53. Sniekers Y. Weinans H. Bierma-Zeinstra S. van Leeuwen J. van Osch G. (2008) Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment - a systematic approach. Osteoarthritis Cartilage 16: 533–541.
54. Still K. Grabowski P. Mackie I. Perry M. Bishop N. (2008) The peroxisome proliferator activator receptor alpha/delta agonists linoleic acid and bezafibrate upregulate osteoblast differentiation and induce periosteal bone formation in vivo. Calcif Tissue Int 83: 285–292.
55. Sverdrup F. Yates M. Vickery L. Klover J. Song L. Anglin C. et al. (2010) Protein geranylgeranylation controls collagenase expression in osteoarthritic cartilage. Osteoarthritis Cartilage 18: 948–955.
56. Tziomalos K. Athyros V. (2006) Fenofibrate: a novel formulation (triglide) in the treatment of lipid disorders: a review. Int J Nanomedicine 1: 129–147.
57. Wang Y. Davies-Tuck M. Wluka A. Forbes A. English D. Giles G. et al. (2009) Dietary fatty acid intake affects the risk of developing bone marrow lesions in healthy middle-aged adults without clinical knee osteoarthritis: a prospective cohort study. Arthritis Res Ther 11: R63.
58. Wang Y. Wluka A. Hodge A. English D. Giles G. O'Sullivan R. et al. (2008) Effect of fatty acids on bone marrow lesions and knee cartilage in healthy, middle-aged subjects without clinical knee osteoarthritis. Osteoarthritis Cartilage 16: 579–583.
59. Ye J. Kiage J. Arnett D. Bartolucci A. Kabagambe E. (2011) Short-term effect of fenofibrate on c-reactive protein: a meta-analysis of randomized controlled trials. Diabetol Metab Syndr 3: 24.